PHILADELPHIA, May 22, 2017 /PRNewswire/ -- Aberdeen
Israel Fund, Inc. (the "Fund") (NYSE MKT: ISL), a closed-end
equity fund, announced today its performance data and portfolio
composition as of April 30, 2017.
The Fund's total returns for various periods through
April 30, 2017 are provided
below. (All figures are based on distributions reinvested at
the dividend reinvestment price and are stated
net-of-fees):
|
Cumulative as of
04/30/17
|
Annualized as of
04/30/17
|
|
1
Month
|
3
Month
|
YTD
|
1
Year
|
3
Years
|
5
Years
|
10
Years
|
Since
Inception
|
|
NAV
|
2.3
|
6.4
|
8.9
|
8.1
|
3.9
|
8.6
|
5.9
|
7.3
|
|
Market
Price
|
5.1
|
12.8
|
14.6
|
17.0
|
3.7
|
8.9
|
4.2
|
6.7
|
|
TA-125
|
1.4
|
5.9
|
4.9
|
4.7
|
-1.1
|
4.3
|
2.8
|
n/a¹
|
On April 30, 2017, the Fund's net
assets amounted to US$82.3 million
and the Fund's NAV per share was US$20.85.
As of April 30, 2017, the
portfolio was invested as follows:
|
Portfolio
Composition
|
Percent of
Net Assets
|
|
Information
Technology
|
31.2
|
|
Financials
|
15.5
|
|
Health
Care
|
13.9
|
|
Materials
|
10.9
|
|
Consumer
Staples
|
7.4
|
|
Real
Estate
|
5.5
|
|
Telecommunications
|
4.8
|
|
Industrials
|
4.7
|
|
Consumer
Discretionary
|
2.9
|
|
Cash
|
3.3
|
The Fund's ten largest equity holdings as of April 30, 2017, representing 68.1% of net assets,
were:
|
Stock
|
Percent
of
Net
Assets
|
|
Check Point Software
Technologies
|
12.5
|
|
Frutarom
Industries
|
9.0
|
|
Ituran Location and
Control
|
8.1
|
|
Perrigo
|
7.0
|
|
Teva Pharmaceutical
Industries
|
6.7
|
|
Azrieli
Group
|
5.3
|
|
Rami Levy
|
5.1
|
|
Nice Systems
Ltd.
|
4.8
|
|
Mizrahi Tefahot
Bank
|
4.8
|
|
Elbit Systems
Ltd.
|
4.8
|
Important Information
Aberdeen Asset Management Inc. has prepared this report based on
information sources believed to be accurate and reliable.
However, the figures are unaudited and neither the Fund, Aberdeen
Asset Managers Limited (the Investment Adviser), nor any other
person guarantees their accuracy. Investors should seek their
own professional advice and should consider the investment
objectives, risks, charges and expenses before acting on this
information. The Investment Adviser and Aberdeen Asset Management
Inc. are each a wholly owned subsidiary of Aberdeen Asset
Management PLC. Aberdeen Asset Management PLC announced on
March 6, 2017 that it entered into an
agreement with Standard Life plc to carry out an all-share merger,
subject to regulatory and other approvals. More information
about the potential merger can be found on Aberdeen's website at
www.aberdeen-asset.com. Aberdeen is a U.S. registered service mark
of Aberdeen Asset Management PLC.
Closed-end funds are traded on the secondary market through one
of the stock exchanges. The Fund's investment return and principal
value will fluctuate so that an investor's shares may be worth more
or less than the original cost. Shares of closed-end funds may
trade above (a premium) or below (a discount) the net asset value
(NAV) of the fund's portfolio. There is no assurance that the Fund
will achieve its investment objective.
Total return figures with distributions reinvested at the
dividend reinvestment price are stated net-of-fees and represents
past performance. Past performance is not indicative of
future results, current performance may be higher or lower.
Holdings are subject to change and are provided for informational
purposes only and should not be deemed as a recommendation to buy
or sell the securities shown. Inception date October 29, 1992.
If you wish to receive this information electronically, please
contact: InvestorRelations@aberdeen-asset.com
¹ There is no since inception figure for the TA-125 Index
because the inception date of the index is January 1, 1999.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/aberdeen-israel-fund-inc-announces-performance-data-and-portfolio-composition-300461716.html
SOURCE Aberdeen Israel Fund, Inc.